Is the NCI MATCH trial a match for gynecologic oncology?

Area of Science:

• Oncology
• Genomics
• Translational Research

Background:

• Precision medicine in cancer aims to tailor treatments based on individual tumor molecular profiles.
• Next-generation sequencing has advanced tumor molecular characterization, but its clinical significance is often unclear.
• Targeted therapies show promise, yet their efficacy in rare mutations (<10%) requires novel trial designs.

Purpose of the Study:

• To review the novel trial designs that facilitated the development and launch of the NCI Molecular Analysis for Therapy Choice (MATCH) trial.
• To clarify the significance of molecular alterations in tumors, particularly those with low-frequency mutations.
• To advance the clinical application of precision medicine in oncology.

Main Methods:

• The NCI MATCH trial (NCT02465060) employs a multi-study, collaborative design.
• It screens tumors for specific molecular features to match patients with targeted therapies.
• The trial focuses on understanding the utility of targeted therapies in tumors with previously unstudied or rare molecular alterations.

Main Results:

• The NCI MATCH trial represents a significant collaborative effort between the NCI and pharmaceutical companies.
• It addresses the challenge of evaluating targeted therapies for rare mutations by screening large patient cohorts.
• The trial design is innovative in its approach to linking molecular alterations to therapeutic response.

Conclusions:

• The NCI MATCH trial is a key initiative in precision medicine, aiming to generate evidence for clinical practice.
• Novel trial designs are crucial for assessing targeted therapies in diverse molecular contexts, including rare mutations.
• This approach seeks to improve cancer treatment by clarifying the significance of molecular profiling.